Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01160770

Acronym

LGS

Enrollment

267

Registered

2010-07-12

Start date

2005-12-31

Completion date

2012-02-29

Last updated

2018-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lennox-Gastaut Syndrome

Keywords

Lennox-Gastaut Syndrome (LGS), Epilepsy, Drop Seizures, Clobazam

Brief summary

The objective of this study is to evaluate the long-term safety and effectiveness of open-label clobazam in the treatment of drop seizures in subjects with LGS.

Detailed description

This multi-center, open-label study is designed to evaluate the long-term safety and effectiveness of clobazam as adjunctive therapy in subjects with LGS. Subjects enrolled in Lundbeck LLC (formerly Ovation Pharmaceuticals, Inc.) sponsored studies 13108A/OV1002/NCT00162981 and 13110A/OV1012/NCT00518713 who either completed the study or who prematurely discontinued were offered the opportunity to rollover into this open-label study. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After 48 hours, investigators will be able to increase, decrease or maintain the subject's dose, up to a maximum target daily dose of 2.0 mg/kg (maximum dose of 80 mg/day). During the treatment period, seizures will be recorded during the week preceding each study visit or 30 days immediately following each study visit (dependent on Amendment approval). The subject or subject's caregiver will record daily counts of seizures, including drop seizures in the subject's seizure diary.

Interventions

DRUGClobazam

Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit. Bottles may be dispensed between visits if necessary. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

2 Years to 60 Years

Healthy volunteers

Inclusion criteria

* The subject or subject's legally authorized representative (LAR) must sign and date the institutional review board (IRB)/independent ethics committee (IEC) approved Informed Consent Form/Health Insurance Portability and Accountability Act (HIPAA) Authorization (if required) prior to study participation. * Previous participation in Lundbeck-sponsored LGS study. * Subject must weigh ≥12.5 kilograms. * Male or female subjects must have been between 2 and 60 years of age at the time of the enrollment in the Phase 3 double-blind study (13110A/OV1012/NCT00518713) or between 2 and 30 years of age at the time of the enrollment in the Phase 2 double-blind study (13108A/OV1002/NCT00162981) study. * If female: * Subject is either not of childbearing potential, defined as premenarchal, postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or if of childbearing potential, must comply with a method of birth control acceptable to the investigator during the study, for at least 4 weeks prior to study entry and for 4 weeks following completion of the study. * Subject is not breastfeeding. * Subjects of childbearing potential must have a negative serum pregnancy test at Study Day 1. * In the investigator's opinion, parent or caregiver must be able to keep an accurate seizure diary.

Exclusion criteria

* Greater than 14 days have elapsed since the subject received his/her last dose of study medication in the previous Lundbeck-sponsored LGS study. * Subject had a serious or severe adverse event in the previous Lundbeck-sponsored LGS study that in the opinion of the investigator was probably or definitely related to clobazam use and precludes safe use of clobazam. * Subject has had an anoxic episode requiring resuscitation within 6 months of study entry. * Subject has a history of an allergic reaction or significant sensitivity to benzodiazepines or to any of the other ingredients in clobazam tablets. * Subject is taking more than 3 concurrent anti-epileptic drugs (AEDs). NOTE: Vagal Nerve Stimulator (VNS) or ketogenic diet is allowed and will not be counted in the three allowed AEDs. * Subject is currently taking long-term systemic steroids (excluding inhaled medication for asthma treatment) or any other daily medication known to exacerbate epilepsy. An exception will be made of prophylactic medication, for example, for idiopathic nephrotic syndrome or asthma. * If the subject is taking felbamate, has been taking it for less than 1 year prior to study entry or previous treatment with felbamate resulted in withdrawal due to liver or bone marrow adverse events. * Subject has experienced an idiosyncratic reaction to an AED, e.g., carbamazepine with resulting aplastic anemia or agranulocytosis, topiramate with resulting metabolic acidosis, felbamate with resulting aplastic anemia or hepatic failure, or lamotrigine with resulting skin irritation and/or rash. * Subject has shown any clinically significant history of hyper-sensitivity to central nervous system (CNS) active medications leading to neurobehavioral aberrations (e.g., increased biting, scratching, kicking, or hitting). * Subject has taken or used any investigational drug or device in the 30 days prior to screening, with the exception of clobazam in a Lundbeck-sponsored study. * Subject has a clinically significant unstable hepatic, hematological, renal, cardiovascular, gastrointestinal, or pulmonary disease or ongoing malignancy. * Subject has a diagnosis of sleep apnea. * Subject has a compromised respiratory function or severe respiratory insufficiency. * Subject has a history of severe muscle weakness, including myasthenia gravis. * Subject has a clinically significant abnormal laboratory value or electrocardiogram (ECG) abnormality. * Subject has progressive lesion confirmed by magnetic resonance imaging (MRI) or computed tomography (CT) scan. * Subject has a history of drug or alcohol abuse. * Subject has a history of poor compliance on past antiepileptic therapy. * Subject has inadequate supervision by parent or guardian. * For any reason, the subject is considered by the investigator to be an unsuitable candidate for the study.

Design outcomes

Primary

Measure	Time frame	Description
Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment	Baseline to month 36	Number of drop seizures was obtained from seizure diaries
Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the Last 30-day Assessment	Baseline to month 36	Number of drop seizures was obtained from seizure diaries

Secondary

Measure	Time frame	Description
Percent of Patients Considered Treatment Responders Defined as Those With a ≥25%, ≥50%, ≥75%, 100% Reduction in Drop Seizures Based on the 7-day Assessment	Baseline to month 36	Number of drop seizures obtained from seizure diaries
Percent of Patients Considered Treatment Responders Defined as Those With a ≥25%, ≥50%, ≥75%, 100% Reduction in Drop Seizures Based on the Last 30-day Assessment	Baseline to month 36	Number of drop seizures obtained from seizure diaries
Investigator Global Evaluations of the Patient's Overall Change in Symptoms	Baseline to month 36	The physician was asked to rate the patient's overall change in symptoms since the beginning of clobazam treatment by checking very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.
Parent/Caregiver Global Evaluations of the Patient's Overall Change in Symptoms	Baseline to month 36	The parent/caregiver was asked to rate the patient's overall change in symptoms since the beginning of clobazam treatment by checking very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.

Participant flow

Recruitment details

Subjects enrolled in the LGS studies 13108A/OV1002/NCT00162981 or 13110A/OV1012/NCT00518713 sponsored by Lundbeck LLC who either completed the study or who prematurely discontinued will have the opportunity to rollover into this open-label study.

Participants by arm

Arm	Count
Clobazam Start dose was 0.5 mg/kg with a maximum of 40 mg/day to be adjusted; administered as tablets twice daily	267
Total	267

Withdrawals & dropouts

Period	Reason	FG000
Overall Study	Adverse Event	10
Overall Study	Death	9
Overall Study	Lack of Efficacy	15
Overall Study	Lost to Follow-up	7
Overall Study	Other Reasons	1
Overall Study	Physician Decision	1
Overall Study	Protocol Violation	2
Overall Study	Study termination or sponsor request	1
Overall Study	Subject/parent/caregiver request	33

Baseline characteristics

Characteristic	Clobazam
Age, Continuous	11.3 years STANDARD_DEVIATION 7.8
Sex: Female, Male Female	104 Participants
Sex: Female, Male Male	163 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	— / —
other Total, other adverse events	241 / 267
serious Total, serious adverse events	115 / 267